AstraZeneca pledges a $15 billion investment in China through 2030, a further commitment to the UK drugmaker’s already sizeable presence in the mainland https://t.co/SUa76XN5vv
— Bloomberg (@business) January 29, 2026
Landmark investment will expand AstraZeneca’s capabilities to discover, develop, and manufacture transformative new treatments in China
Investment will support delivery of AstraZeneca’s 2030 ambition
AstraZeneca today announced $15 billion investment in China through 2030 to expand medicines manufacturing and R&D. This investment will leverage the country’s scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations to deliver cutting-edge treatments to patients across China and globally.
Keir Starmer, UK Prime Minister, said: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements. AstraZeneca’s expansion and leadership in China will help the British manufacturer continue to grow – supporting thousands of UK jobs. The multi-billion pound investment announced today from AstraZeneca, alongside partnerships from some of our country’s leading universities, furthers research and development in the UK which is helping to power our world class life sciences sector.”
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Today’s landmark investment of $15 billion begins an exciting next chapter for AstraZeneca in China, which has become a critical contributor to scientific innovation, advanced manufacturing, and global public health. By expanding our capabilities in breakthrough treatments like cell therapy and radioconjugates, we will strengthen our contribution to China’s high-quality development and, most importantly, bring next-generation modalities to patients.”